27 Noteworthy Myocarditis Case Studies

Select handful from the compilation of 143 studies that have broader implications beyond being a 'routine' case of vaccine myo/pericarditis

The following are studies that show more than just a “routine” case of vaccine myocarditis, organized into the following categories:

• Long Term Damage - Contrary to popular mainstream opinion that vaccine myocarditis is a transitory phenomenon.

• Rare & Scary Forms of Myocarditis - Not exactly the routine mild myocardial inflammation from the good ole days of your grandfather’s youth.

• Multiple Severe Adverse Events: Myocarditis + Additional ‘Goodies’ - Whoever said that the vaccine can only hit you with one severe pathology?

• Case Series Studies - If one hospital gets 8 myo patients in an 8-week span, the rate of myo/vaccine doses is definitely far, far more prevalent than the mere trifling 1/50,000 claimed by the FDA/CDC.

• Identifies the Spike Protein as the Potential Cause of Vaccine Myocarditis - As opposed to the FDA/CDC who are still struggling mightily to resolve the profound mystery of how a ‘safe & effective’ vaccine could possibly cause such a horrific mild adverse event.

• We’re Flying Blind - Highlighting Medical Community Ignorance of How the Vaccines ‘Work’ - No explanation necessary.

• Miscellaneous - Everything else.

(Note: The number in () before the study title is from the full compilation of 143 case reports.)

***********************************************************************************************

‘Mild’ Long Term Damage:

The following case studies show that mild myocarditis may often be mild long haul ‘transient’ myocarditis:

Study #1: (110) Cardiac magnetic resonance findings in acute myocarditis after mRNA COVID-19 vaccination

Author: Sano et al

Country: Japan

Date Published Online: 2/11/22

Vaccine: Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/35169401/

Case: “It showed improvement in myocardial edema but persistence of LGE which may indicate irreversible fibrosis.”

Study #2: (149) Case Report: Transient Increase of CMR T1 Mapping Indices in a Patient With COVID-19 mRNA Vaccine Induced Acute Myocarditis

Author: Ansari et al

Country: Germany

Date Published Online: 5/16/22

Vaccine: Moderna

Link: https://pubmed.ncbi.nlm.nih.gov/35571183/

Case: “Scarred myocardium reflecting chronic myocarditis continued to show elevated T1 times.”

Study #3: (129) COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up

Author: Puchalski et al

Country: Poland

Date Published Online: 3/15/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35329143/

Case: “COVID-19-vaccine-induced myocarditis seems to be a mild disease with fast clinical recovery, but the complete resolution of the inflammatory process may last over 3 months.”

***********************************************************************************************

Rare & Scary: Recherché Myocarditis

(The odds of meeting someone who knows what that word means is roughly equivalent to the odds of one of these types of myocarditis occurring)

Study #4: (94) First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction

Author: Ameratunga et al

Country: NZ

Date Published Online: 1/3/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/34978002/

Case: “The clinical and pathological observations from a case of fatal fulminant necrotising myocarditis in a 57-year-old woman, following the first dose of the Pfizer-BioNTech vaccine, are described. Other causes have been discounted with reasonable certainty.”

“A previously well 57-year-old woman received the first Pfizer-BioNTech vaccine in July 2021. The following day she experienced increasing lethargy and had to leave work early because of worsening fatigue. She had one episode of breathlessness and complained of a stiff neck as well as upper limb pain. She had a sore throat but pointed to her sternum. During the remainder of the day, she became increasingly unwell. The following day she consulted her primary care physician with a sore throat, back pain, fatigue and an episode of haematuria, which had occurred the previous night. She had difficulty getting out of the car and experienced a fall at the family physician’s surgery. She did not complain of palpitations.”

“Autopsy Findings: […] Histological examination of the heart sections showed fulminant necrotizing eosinophilic myocarditis (Fig. 1, bottom left and bottom right). There were multifocal aggregates of lymphoid cells, histiocytes and abundant eosinophils with focal myocyte necrosis in the free walls of both ventricles, inter-ventricular septum and around the conduction system (sino-atrial and atrio-ventricular nodes). No parasitic organisms or giant cells were identified. The eosinophilic infiltrate would make autoimmune myocarditis less likely. There was no evidence of eosinophils in other organs or eosinophilic vasculitis. Histological examination of the left pleural space mass showed a thymoma, WHO subtype AB.”

Study #5: (132) Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19

(Maybe mixing and matching vaccines wasn’t such a good idea after all…)

Author: Kang et al

Country: Korea

Date Published Online: 3/20/22

Vaccine: Pfizer, AstraZeneca

Link: https://pubmed.ncbi.nlm.nih.gov/35334625/

Case: “A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical signs or have laboratory findings of concomitant infection before or after vaccination. Heart transplantation was performed because her heart failed to recover with venoarterial extracorporeal oxygenation support. Organ autopsy revealed giant cell myocarditis, possibly related to the vaccines. Clinicians may have to consider the possibility of the development of giant cell myocarditis, especially in patients with rapidly deteriorating cardiac function and myocarditis symptoms after COVID-19 vaccination.”

Study #6: (93) Kounis syndrome associated with BNT162b2 mRNA COVID-19 vaccine presenting as ST-elevation acute myocardial infarction

Author: Şancı et al

Country: Turkey

Date Published Online: 1/1/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35191390/

Case: “We present the case of a 22-year-old woman with no known co-morbid diseases who had previous egg and tomato allergy and no known prior drug allergies. The patient presented to our emergency department with complaints of “palpitations” and “uneasiness of the chest” after her first dose of COVID-19 vaccine (BNT162b2, Pfizer–BioNTech). Complaints started approximately after 15 minutes of vaccination.”

"To the best of our knowledge, this is the first case of an allergic reaction that resulted in ST-segment elevation secondary to mRNA-based coronavirus vaccine. Allergic reactions result from Kounis syndrome reported with other vaccines such as inactive COVID-19 vaccines (4, 5). Furthermore, similar to these cases, myocardial infarction after Moderna vaccination, which also might be a Kounis syndrome, has been reported previously (6).

Kounis syndrome is the concurrence of acute coronary syndrome with conditions associated with mast cell activation, including allergic or hypersensitivity and anaphylactic or anaphylactoid mechanisms (7). This syndrome’s pathophysiology is linked to inflammatory mediators, such as histamine; neutral proteases, including tryptase, chymase, and cathepsin-D; arachidonic acid products; platelet-activating factor; and a variety of cytokines and chemokines released during the mast-cell activation and classified into three variants (8). Type 1 patients have no risk factor for ischemic heart diseases and pathophysiological changes linked to coronary artery vasospasm. Type 2 patients have pre-existing atheromatous diseases and pathophysiological changes described with plaque erosion resulting in vasospasm or infarction. Finally, type 3 patients have previous coronary artery stents, and stent thrombosis occurs owing to platelet activation. Our patient was identified as the type 1 variant owing to a lack of a previous history of heart disease, and coronary angiography showed no coronary thrombosis or stenosis. The type 1 variant has a better prognosis, which we observed in our patient.

Kounis syndrome is fundamentally linked to allergic reactions and should be expected to be seen in patients prone to allergy. Our patient had previous tomato and egg allergies, which suggests that she could have unknown drug or vaccine allergies that can manifest easily because of her atopic nature. Furthermore, coronary angiography showed no abnormalities which suggests this was a short coronary vasospasmic episode, most likely because of allergy.

***********************************************************************************************

Multiple Severe Adverse Events: Myo/Pericarditis + Additional Goodies

Study #7: (148) Post Covıd-19 Vaccınatıon Inflammatory Syndrome: A Case Report

[Myo Together with Myositis & Muscle Necrosis]

Author: Durucan et al

Country: Turkey

Date Published Online: 5/12/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35556127/

Case: “A previously healthy 24-year-old male patient was referred to our clinic with bilateral lower extremity pain and dark urine, which developed two weeks after receiving the second dose of BNT162b2 vaccine against SARS-CoV-2. Laboratory tests indicated rhabdomyolysis. Lower extremity magnetic resonance imaging was compatible with myositis. Myositis-related antibodies were negative. Biopsy taken from gastrocnemius muscle revealed muscle necrosis and striking expression of major histocompatibility complex class I antigen. He was successfully treated, and his complaints resolved. One week later at follow-up, he reported new-onset exertional dyspnea with palpitations. ST-segment depressions were spotted on electrocardiography. Troponin T was found elevated as 0.595 ng/mL (normal <0.014 ng/mL). Echocardiography showed hypokinetic left ventricle with ejection fraction of 40%, and pericardial effusion of 2mm. An appropriate treatment plan was formulated for the diagnosis of myocarditis, eventually the patient recovered within ten days. BNT162b2 mRNA vaccine was felt to cause the aforementioned condition since no other etiology could be identified. Although it is known that BNT162b2 may induce myocarditis, myositis concomitant myocarditis appears to be a very rare adverse effect of this vaccine.”

Study #8: (104) Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2

Author: Plüß et al

Country: Germany

Date Published Online: 1/18/22

Vaccine: AstraZeneca

Link: https://pubmed.ncbi.nlm.nih.gov/35116025/

Case: “A 67-year-old Caucasian female with a past medical history of atrial fibrillation, hypertension, obesity, degenerative knee joint disease, and no documented history of COVID-19 received a first dose of ChAdOx1 nCoV-19 vaccination. The patient had no allergies, no history of immune deficiency, no recent infectious disease, and denied illicit drug use. Two weeks after vaccination, the patient suffered from fever, weakness and arthralgia of the knees, hips and shoulders (Figure 1A). After additional 3 weeks, the patient was admitted to a community hospital with stable vital parameters and normal physical examination (Figure 1A). Computed tomography (CT) scans of the chest and abdomen revealed reactive mediastinal lymphadenopathy and hepatic steatosis.”

“Cardiac magnetic resonance imaging (MRI) confirmed diagnosis of pericarditis with circumferential thickening and contrast enhancement of the entire pericardium at late gadolinium enhancement (LGE, Figure 1C) (13, 14). Based on these imaging findings, heart involvement with viral pericarditis was suspected. EBV serology was compatible with past infection (anti-EBV-VCA-IgG: positive, anti-EBV-IgM: negative), confirmed by PCR with no detectable EBV-DNA. However, serology of CMV was compatible with active CMV infection (anti-CMV-IgG: >250 IU/mL, anti-CMV-IgM: positive), confirmed by PCR with detectable CMV viremia (415 IU/mL).”

“In summary, we here present the clinical course of a patient with CMV reactivation and pericarditis in temporal association with ChAdOx1 nCoV-19 vaccination against SARS-CoV-2.”

Study #9: (115) COVID-19 Vaccine-Induced Multisystem Inflammatory Syndrome With Polyserositis Detected by FDG PET/CT

[Pericarditis + Multisystem Inflammatory Syndrome + Polyserositis]

Author: Lee SJ et al

Country: Korea

Date Published Online: 2/16/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35175945/

Case: “In this case, a 65-year-old man with BNT162b2 mRNA COVID-19 vaccination underwent 18F-FDG PET/CT to evaluate prolonged fever and elevated serum C-reactive protein. PET/CT showed hypermetabolic infiltration in the pericardium and peritoneum suggesting immune-mediated pericarditis and peritonitis. After administration of high-dose corticosteroids, the patient's symptom resolved. This case suggests that multisystem inflammatory syndrome and polyserositis can be induced by the COVID-19 vaccine.”

Study #10: (116) American Journal of Case Reports | Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report - Article abstract #934399

[He got hit with pretty much every side known major vaccine side effect]

Author: Al-Rasbi et al

Country: Oman

Date Published Online: 2/17/22

Vaccine: Pfizer

Link: https://www.amjcaserep.com/reprintOrder/index/idArt/934399

Case: “A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis complicated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks.”

Study #11: (89) Lessons of the month 3: Haemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19)

[Pericarditis + HLH]

(In a nutshell, HLH is when your macrophages - a type of immune cell that basically gobbles up viruses/bacteria & anything else that’s not supposed to be floating around - become ‘disoriented’ and think that red blood cells are yummy & start eating them up.)

Author: Cory et al

Country: UK

Date Published Online: 12/4/21

Vaccine: AstraZeneca

Link: https://pubmed.ncbi.nlm.nih.gov/34862234/

Case: “A 36-year-old woman presented to hospital 9 days after receiving her first dose of the ChAdOx1 nCoV-19 vaccine with fever, myalgia and a sore throat. She was previously fit and well with no prior vaccine reactions.

There was no clinical response to initial treatment with intravenous (IV) antibiotics. Microbiology tests including for COVID-19 were negative. At day 5, she developed pleuritic pain and a pericardial rub. Echocardiography and subsequent cardiac magnetic resonance imaging showed evidence of constrictive pericarditis. Computed tomography revealed gross hepatomegaly and moderate splenomegaly. Blood tests showed raised inflammatory markers, deranged clotting, low platelets and a marked hyperferritinaemia.

A presumptive diagnosis of a multi-system inflammatory disorder secondary to recent COVID-19 vaccination was made and high-dose IV methylprednisolone initiated. Following a high ‘H score’ of 70%–80% a diagnosis of secondary haemophagocytic lymphohistiocytosis (HLH) was made. She was treated with IV immunoglobulin with subsequent clinical response.

HLH is a rare syndrome of acute and rapidly progressive systemic inflammation characterised by cytopenias, excessive cytokine production and hyperferritinaemia. The adult form has multiple triggers, including recent vaccination. This case prompts awareness among clinicians of HLH as a rare complication of COVID-19 vaccination but should not discourage individuals from vaccination.”

***********************************************************************************************

Mild Fatal Myocarditis

Study #12: (56) Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination

Author: Ujueta et al

Country: US

Date Published Online: 9/7/21

Vaccine: J&J

Link: https://pubmed.ncbi.nlm.nih.gov/34514078/

Case: “A 62-year-old Caucasian female visiting from Uruguay presented to the emergency department complaining of progressive body aches, weakness and worsening fatigue approximately 4 days after administration of the Ad26.COV2.S (Janssen Johnson & Johnson®) viral vector COVID-19 vaccine.”

“The autopsy was performed 9-hours postmortem. […] Microscopic view of the myocardial biopsy showing scattered positive CD3 immunostaining supporting T cell infiltration (Fig. 1b). Multiple immunohistochemistry staining like CD163 supports the diagnosis of lymphohistiocytic myocarditis with sparse eosinophils (Supplementary Fig. 2).”

“This case suggests a potential relationship between the viral vector COVID-19 vaccine and the patient’s lymphohistiocytic myocarditis resulting in severe biventricular cardiomyopathy and death. Although there have been no previous reports of cardiac involvement with the viral vector vaccine, the timing of the event and the lack of other identifiable etiologies suggest a relationship.”

Study #13: (113) Autopsy Histopathologic Cardiac Findings in Two Adolescents Following the Second COVID-19 Vaccine Dose | Archives of Pathology & Laboratory Medicine

Author: Gill et al

Country: US

Date Published Online: 2/14/22

Vaccine: Pfizer

Link: https://meridian.allenpress.com/aplm/article/doi/10.5858/arpa.2021-0435-SA/477788/Autopsy-Histopathologic-Cardiac-Findings-in-Two

Case: “Objective: To examine the autopsy microscopic cardiac findings in adolescent deaths that occurred shortly following administration of the second Pfizer-BioNTech COVID-19 dose to determine if the “myocarditis” described in these instances has the typical histopathology of myocarditis.

Design: Clinical and autopsy investigation of two teenage boys who died shortly following administration of the second Pfizer-BioNTech COVID-19 dose.

Results: The microscopic examination revealed features resembling a catecholamine-induced injury, not typical myocarditis pathology.

Conclusions: The myocardial injury seen in these post-vaccine hearts is different from typical myocarditis and has an appearance most closely resembling a catecholamine-mediated stress (toxic) cardiomyopathy. Understanding that these instances are different from typical myocarditis and that cytokine storm has a known feedback loop with catecholamines may help guide screening and therapy.”

Study #14: (142) Intermittent complete heart block with ventricular standstill after Pfizer COVID-19 booster vaccination: A case report

[Multiple mild ‘complete heart block with ventricular standstill’ events (ie heart stopped beating altogether) plus other exciting clinical developments]

Author: Kimball et al

Country: US

Date Published Online: 4/20/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35475120/

Case: “A 57‐year‐old male with a past medical history of hypertension on valsartan and recent COVID‐19 booster vaccination presented to the emergency department (ED) by ambulance for evaluation of syncope. The patient had received his third dose of the Pfizer‐BioNtech COVID‐19 vaccine the previous day. He subsequently experienced multiple syncopal events for which 911 was called. During emergency medical services transport, the patient had another syncopal episode with reported asystole on the cardiac monitor; this episode resolved spontaneously and cardiopulmonary resuscitation (CPR) was not performed.”

“Shortly after being attached to the cardiac monitor, the patient lost consciousness and went into complete heart block with ventricular standstill with loss of pulses (Figure 2). CPR was initiated; however, before completion of the first round of compressions the patient regained consciousness with return of spontaneous circulation and normal sinus rhythm. The decision was made to intubate the patient for airway protection. While being prepared for intubation, the patient again developed complete heart block with ventricular standstill. CPR was restarted and the patient was given 1 mg of intravenous epinephrine.”

“Given the patient's recurrent episodes of complete heart block with ventricular standstill, the decision was made to place a transvenous pacemaker (TVP) for sustained pacing.”

“Cardiac magnetic resonance imaging (MRI) was more illuminating with evidence of global left ventricular inflammation and late gadolinium enhancement of the basal septum consistent with myocarditis. This diagnosis was confirmed by endomyocardial biopsy that demonstrated lymphocytic myocarditis with negative immunohistochemical staining for amyloid and viral etiologies including parvovirus, adenovirus, herpes simplex virus, and cytomegalovirus.”

Study #15: (112) Biopsy-Proven Fulminant Myocarditis Requiring Mechanical Circulatory Support Following COVID-19 mRNA Vaccination

[Ultra Ultra Mild Myocarditis: The patient didn’t die! His heart merely failed and required ‘mechanical circulatory support’ (a device typically used as a temporary ‘Band-Aid’ for patients awaiting a heart transplant)]

Author: Kazama et al

Country: Japan

Date Published Online: 2/13/22

Vaccine: Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/35187464/

Case: “A 48-year-old woman suffered from cardiogenic shock with fulminant myocarditis following the second dose of COVID-19 vaccine (mRNA-1273). Venoarterial extracorporeal membrane oxygenation and Impella support were essential in achieving hemodynamic stability. Endomyocardial biopsy revealed lymphocytic infiltration with predominant immunostaining for CD8- and CD68-positive cells. The left ventricular ejection fraction improved significantly after treatment with mechanical circulatory support. Myocarditis following COVID-19 mRNA vaccination may also occur in middle-aged women; it may be fulminant and require mechanical circulatory support. Although our results suggest the involvement of cytotoxic T lymphocytes and macrophages, further investigation is needed before these can be established as pathogenetic mechanisms.”

***********************************************************************************************

Case Series Studies

These are case series studies - studies that instead of reporting on a single case report on multiple cases treated - where one hospital or healthcare facility had a bunch of myocarditis cases. One hospital having, say, 8 cases of myocarditis in a 10 week span suggests that the overall # of myocarditis cases is orders of magnitude higher than the official #’s, or even the # of cases reported to VAERS. Another significant characteristic in some of these is that they were available very early on, which shows that the FDA are a bunch of corrupt and malevolent liars - the FDA scientists definitely understood the prior point, yet they maintained for months and months that first myo didn’t exist and then when that became untenable in light of the widespread reporting all over the FDA switched to “mild & rare”.

Study #16 (10) Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines - PubMed

(5 cases / 1 location)

Author: Vidula et al

Country: US

Date Published Online: 6/10/21

Vaccine: Pfizer, Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/34277198/

Study #17: (22) Myocarditis Associated with mRNA COVID-19 Vaccination | Radiology

(5 cases / 1 location)

Author: Starekova et al

Country: US

Date Published Online: 6/20/21

Vaccine: Pfizer, Moderna 

Link: https://pubs.rsna.org/doi/10.1148/radiol.2021211430

Study #18: (57) Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series - PMC

(5 cases / 1 location)

Author: Patel Y et al

Country: US

Date Published Online: 9/9/21

Vaccine: Pfizer, Moderna

Link: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8425992/

Study #19: (63) Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination - PubMed

(30 cases, 1 location, all cases occurred between January 1, 2021 - March 31, 2021)

Author: Aye et al

Country: Singapore

Date Published Online: 9/30/21

Vaccine: Pfizer, Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/34586408/

Case: “Consecutive patients admitted in a tertiary hospital in Singapore between 1 January 2021 and 31 March 2021, with onset of cardiac manifestations within 14 days following COVID-19 vaccination were studied.”

“Thirty patients were included in the study cohort, with 29 diagnosed with AMI (14 ST-segment elevation and 15 non-ST-segment elevation MI) and 1 with myocarditis. Median hospital stay was 4.5 days (IQR 4.0–6.2). Five patients developed heart failure, two had cardiogenic shock, three intubated, and one had cardiovascular-related mortality.”

Study #20: (78) Myocarditis Following mRNA COVID-19 Vaccine - PubMed

(At least 35 with a “diagnosis of myopericarditis associated with Pfizer COVID-19 mRNA vaccine”, 1 location)

(The original study reported 13 patients with myopericarditis “aged <18 years presenting with severe chest pain and signs of myopericarditis within 1 week of receiving the second dose of the Pfizer COVID-19 vaccine between April 1, 2021, and June 21, 2021,” published online July 3, 2021)

Author: Schauer et al

Country: US

Date Published Online: 3/25/22

Vaccine: Pfizer

Link: https://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext 

Case: “This case review includes patients younger than 18 years of age presenting to Seattle Children's Hospital with chest pain and elevated serum troponin level from April 1, 2021, to January 7, 2022, within 1 week of receiving the second dose of the Pfizer COVID-19 mRNA vaccine.”

“A total of 35 patients with the diagnosis of myopericarditis associated with Pfizer COVID-19 mRNA vaccine were followed at our institution. Twelve patients were excluded, as they never had cardiac MRI scans due to delayed presentation after initial symptoms resolved or admission to other centers. Six patients were excluded, as they did not have a follow up cardiac MRI, either because they followed up out of state or a study is still pending. One patient was excluded, as initial cardiac MRI was performed 3 weeks after presentation. Sixteen patients who had both acute-phase and follow-up cardiac MRIs available for review comprised the final cohort.”

(Note: There are a few more case series studies that I didn’t include in the massive compilation that have a decent # of cases)

***********************************************************************************************

Identifies the Spike Protein as the Potential Cause of Vaccine Myocarditis

This is important in light of the continuing attempt by the mainstream medical community to deny that the vaccines’ spike protein is toxic or pathogenic:

Study #21: (100) A Case of Acute Viral Pericarditis Complicated With Pericardial Effusion Induced by Third Dose of COVID Vaccination

Author: Zaki et al

Country: Qatar

Date Published Online: 1/13/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35165640/

Case: “But on the other hand, pericarditis is reported to occur in rare instances of COVID-19 infection, and this may be attributed to the pro-inflammatory effects of the spike protein.”

“Although we cannot mention a direct effect, it is essential to note a potential adverse reaction to vaccine administration following the expression of SARS-CoV-2 spike protein-induced from the vaccine's mRNA.”

Study #22: (65) A Case of Acute Pericarditis After COVID-19 Vaccination

Author: Sonaglioni et al

Country: Italy

Date Published Online: 10/1/21

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35387019/

Case: “Although a direct effect cannot be stated, it is important to report a potential adverse vaccine reaction effect that could be associated with the expression of SARS-CoV-2 spike protein induced from the mRNA of the vaccine.”

***********************************************************************************************

We’re Flying Blind - Highlighting Medical Community Ignorance of How the Vaccines ‘Work’

Ignorance abounds!

How do Genetics Influence Vaccine Outcomes:

Study #23: (140) COVID Vaccine-Associated Myocarditis in Adolescent Siblings: Does It Run in the Family?

Author: Moosman et al

Country: NZ

Date Published Online: 4/14/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35455360/

Case: “Patient 1 is a 14-year-old male who presented to his general practitioner with acute-onset left-sided chest pain three days after receiving the second dose of the Pfizer–BioNTech COVID-19 vaccine. The patient was previously healthy with no comorbid conditions and no significant family history of cardiac disease.”

“Cardiac MRI 5 days following vaccination confirmed active myocarditis by Lake Louise criteria, including myocardial oedema on T2-weighted imaging and non-ischemic myocardial injury on late gadolinium-enhanced imaging [13]. These changes were focal, involving the inferior basal third of the left ventricle and the posterior obtuse marginal surface (Figure 2A).”

“Patient 2 is a 12-year-old male with no previous medical history or comorbid conditions and is the younger sibling of patient 1 (details in Table 1). Patient 2 presented one week following his brother’s admission with acute left-sided chest pain that developed 48 h after receiving the second dose of the Pfizer–BioNTech COVID-19 vaccine.”

“Cardiac MRI 5 days following vaccination was similar to that of the older sibling. There was a large region of full-thickness myocardial oedema in the inferior and posterior obtuse marginal surfaces of the heart. Late gadolinium-enhanced imaging confirmed the presence of non-ischemic myocardial injury in these regions (Figure 2B).”

Can Drug-on-Drug Interactions Mediate any of the Vaccine Side Effects:

Study #24 (136) Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

Author: Terán Brage et al

Country: Spain

Date Published Online: 3/31/22

Vaccine: Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/35378738/

Case: “Case report 62-year-old woman diagnosed in September 2019 of lung adenocarcinoma stage IV with bilateral lung and lymph node involvement, carrier of an EGFR mutation (Ex19Del) on treatment with osimertinib. She attended emergency department for fever and hypotension 24 h after administration of the third dose of Moderna® COVID-19 vaccine in the context of acute myocarditis with evidence of severe left ventricular (LV) dysfunction in cardiogenic shock. She required vasoactive support, non-invasive mechanical ventilation, corticotherapy, immunoglobulins and subsequent ventricular support with Impella, with improvement of the clinical picture after 3 days. Cardiac magnetic resonance imaging (MRI) showed evidence of global myocardial oedema compatible with acute myocarditis. Coronary CT showed a lesion in the anterior descending coronary artery requiring revascularization. A few days later, she presented febrile symptoms with isolation of Staphylococcus aureus in the central line catheter and antibiotherapy with cloxacillin was started, with subsequent resolution of the infectious symptoms. Conclusion This is an exceptional and controversial case of fulminant myocarditis probably related to the Modern COVID-19 vaccine in a patient diagnosed with metastatic lung adenocarcinoma on treatment with osimertinib. An increasing number of cases of myocarditis and pericarditis have been reported following vaccination with COVID-19 mRNA vaccines. In addition, retrospective data have shown an increased risk of QT prolongation and heart failure in patients treated with tyrosine kinase inhibitors. Hence, the need for close monitoring of cardiac function during treatment of these patients. Future studies will be necessary to evaluate unknown adverse reactions of these vaccines and their possible interaction with other antineoplastic drugs.”

They haven't the foggiest idea of what actually happened (read the full case report):

Study #25: (106) COVID-19 mRNA Vaccination Mimicking Heart Attack in a Healthy 56-Year-Old Physician

Author: Xinias et al

Country: Greece

Date Published Online: 1/27/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35200439/

Case: “We report our experience regarding a 56-year-old physician who developed severe symptoms mimicking a heart attack a few days after receiving the second dose of the new mRNA vaccine of Pfizer-BioNTech for COVID-19 protection. The patient is a healthy individual with no comorbidities and a normal clinical and laboratory profile. Five days after receiving the second dose on his left shoulder, he manifested sudden, severe pain on the whole left arm which lasted for about one hour, gradually intensifying and migrating to the chest and presenting as severe angina or heart attack. All work-up, however, was negative, with no evidence of ischemic heart attack or myocarditis. Severe acute symptoms lasted for about 20 h and completely resolved after 36 h. Although myocarditis as a potential side effect of the vaccine with associated heart pain has been identified, chest pain mimicking heart attack with otherwise normal workup has not been reported. Physicians must consider this likely rare and self-resolving symptom in order to increase awareness and prevent themselves and their patients from increased anxiety and unnecessary laboratory investigations.”

***********************************************************************************************

Miscellaneous & Noteworthy

Study #26: (59) Takotsubo syndrome after receiving the COVID-19 vaccine

(Vaccine can break your heart. Literally. Takotsubo = Broken Heart Syndrome)

Author: Fearon et al

Country: US

Date Published Online: 9/14/21

Vaccine: Moderna 

Link: https://pubmed.ncbi.nlm.nih.gov/34539938/

Case: “This case demonstrates the development of takotsubo syndrome (TTS) after administration of the COVID-19 vaccine. A 73-year-old woman with recently diagnosed myocardial infarction with no obstructive coronary atherosclerosis (MINOCA) presented with typical chest pain starting less than a day after receiving the Moderna vaccine. She had troponin elevations and new ST-segment abnormalities. Transthoracic echocardiogram (TTE) findings were consistent with mid-ventricular TTS. Treatment included diuretics, beta-blockers, and angiotensin receptor blockers. Prior to discharge, repeat imaging showed improvement in systolic function. This case presents a post-menopausal woman with a recent diagnosis of MINOCA who developed TTS shortly after receiving the COVID-19 vaccine. Risk factors including sex, age, MINOCA, anxiety about the vaccine, and possibly the vaccine itself may have all contributed to the TTS presentation. TTS may occur after COVID-19 vaccination, and appreciation of this potential rare association is important for evaluating vaccine safety and optimizing patient outcomes.”

Last but certainly not least: Myocarditis isn’t ageist or sexist - Myocarditis in an *80yo Woman* (!!), with an added bonus of still not yet recovered after 3 months (bolded):

Study #27: (97) Fulminant myocarditis following coronavirus disease 2019 vaccination: a case report

Author: Agdamag et al

Country: US

Date Published Online: 1/10/22

Vaccine: Pfizer

Link: https://pubmed.ncbi.nlm.nih.gov/35088026/

Case: “An 80-year-old female with no significant cardiac history presented with cardiogenic shock and biopsy-proven fulminant myocarditis within 12 days of receiving the BNT162b2 COVID-19 vaccine. She required temporary mechanical circulatory support, inotropic agents, and high-dose steroids for stabilization and management. Ultimately, her cardiac function recovered, and she was discharged in stable condition after 2 weeks of hospitalization. A repeat cardiac MRI 3 months after her initial presentation demonstrated stable biventricular function and continued improvement in myocardial inflammation.”